Feasibility of Transcranial Direct Current Stimulation (tDCS) in the Treatment of Adult Attention Deficit Disorder (ADD).

Phase 1UnknownNCT02206516

Tel-Aviv Sourasky Medical Center20 enrolled

Overview

This study aims at combining imaging techniques and clinical evaluations to assess clinical change as well as brain changes that occur as a result of brain stimulation in adult attention deficit disorder.

This study will use clinical measures and cognitive tasks covering 3 different functional domains during functional magnetic resonance imaging (fMRI), ElectroEncephaloGram (EEG) and Ultrasound tagged near infrared spectroscopy (UT-NIRS), to assess functional brain changes as a result of a treatment protocol with Transcaranial direct current stimulation (tDCS) in adults suffering from attention deficit disorder (ADD).

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Adult Attention Deficit Disorder

Interventions

Transcranial Direct Current StimulationDEVICE

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients between the ages of 18-65(male and female) 2. Diagnosed as suffering from Attention-Deficit Hyperactivity Disorder according to the DSM IV 3. Patients taking medication for ADHD will give their consent to stop those medication 48 before entering the study and throughout the daily treatments. 4. Gave informed consent for participation in the study 5. If referred by the treating psychiatrist, he or she approves of the subjects participation in the study Exclusion Criteria: 1. Suffering from other diagnosis on axis 1 2. History of drug or alcohol abuse during the last year 3. Inability to achieve satisfying level of communication with the subject

Locations (1)

TASMC

Tel Aviv, Israel

Outcomes

Primary Outcomes

Efficacy will be examined by the change in the CAARS questionnaire from the baseline visit to the determination visit in the treatment group compared to the control group.

Time frame: 6 weeks

Secondary Outcomes

changes in functional activity after 4 weeks of tDCS treatment during response inhibition

ROI analysis of right Inferior frontal cortex will be measured during response inhibition in the Go/Nogo task at the end of the 4 weeks of treatment and will be compared to baseline measures.

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.